On February 23rd, HLI hosted another engaging session as part of its Seminar Series, featuring Samuel Leung, a PhD student in Bioinformatics from the Computational Biology and part of Wang’s Lab at HLI. Samuel’s talk, titled Benchmarking and Developing Tools for Cardiovascular Drug Repurposing, explored an innovative approach to tackling the global heart disease crisis.
Cardiovascular disease remains the leading cause of death worldwide, yet developing new treatments is often slow and costly. Samuel’s talk shed light on a promising solution: repurposing existing drugs. This approach focuses on finding new uses for drugs that have already been approved and proven to be safe, significantly reducing the time and costs involved in clinical trials.
Traditional methods of drug repurposing can be hit-or-miss, often relying on chance observations of how a drug affects conditions it wasn’t originally designed to treat. These methods don’t offer much insight into how or why a drug works in a different context, making it difficult to predict if it will help with a new disease. Samuel’s research aims to improve these methods by using computational tools that better identify promising treatments for heart disease.
By evaluating and refining these tools, Samuel is helping pave the way for faster and more cost-effective development of new cardiovascular therapies. This research is an exciting step toward making heart disease treatments more accessible and efficient, ultimately saving lives on a global scale.
This session provided a fascinating look at how modern technology is being used to improve healthcare, and Samuel’s work is a crucial contribution to the field of cardiovascular treatment.
If you want to connect with Samuel and learn more about his work, feel free to visit his LinkedIn profile here: https://www.linkedin.com/in/sleung124/